PRESS RELEASE Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 Paris, France - May 30, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced tod - SNY - Document - PDFSEARCH.IO

First Page	Meta Content
	PRESS RELEASE Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 Paris, France - May 30, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced tod Add to Reading List Document Date: 2014-05-30 02:45:11 Open Document File Size: 203,56 KB Share Result on Facebook City New York / Paris / / Company Bayer / Genzyme Corporation / Sanofi Company / / Country France / United States / / Event Company Listing Change / / IndustryTerm therapeutic solutions / consumer healthcare / pharmaceutical / healthcare / diabetes solutions / / MedicalCondition rare and debilitating diseases / rare diseases / diabetes / multiple sclerosis / MS / / Organization U.S. Food and Drug Administration / FDA / / Position global healthcare leader / / Product LemtradaTM / / ProvinceOrState Mississippi / / Technology therapeutic solutions / / URL www.genzyme.com / / SocialTag Alemtuzumab Pharmaceutical industry Pharmacology Genzyme Sanofi Pharmaceutical sciences

PRESS RELEASE Genzyme’s Lemtrada Resubmission Accepted for Review by FDA - Agency action expected in Q4 2014 Paris, France - May 30, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced todAdd to Reading List